The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Amphotericin B
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00118-7 · Cited by 2,113
Gref, R., Lück, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., Blunk, T., & Müller, R. H. (2000) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00156-3 · Cited by 1,723
Nanosuspensions as particulate drug formulations in therapy
Müller, R. H., Jacobs, C., & Kayser, O. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00118-6 · Cited by 1,370
Self-citation(1999) · Journal of Equine Veterinary Science · doi:10.1016/s0737-0806(99)80080-x · Cited by 801
Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles
Papahadjopoulos, D., Vail, W. J., Jacobson, K., & Poste, G. (1975) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(75)90299-0 · Cited by 545
Amphotericin B: current understanding of mechanisms of action
Brajtburg, J., Powderly, W. G., Kobayashi, G. S., & Medoff, G. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.2.183 · Cited by 504
Amphotericin B: spectrum and resistance
Ellis, D. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.7 · Cited by 473
Mortality and Costs of Acute Renal Failure Associated with Amphotericin B Therapy
Bates, D. W., Su, L., Yu, D. T., Chertow, G. M., Seger, D. L., Gomes, D. R. J., Dasbach, E. J., & Platt, R. (2001) · Clinical Infectious Diseases · doi:10.1086/319211 · Cited by 451
Amphotericin B: time for a new “gold standard”
Saravolatz, L. D., Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H., & Cohen, S. H. (2003) · Clinical Infectious Diseases · doi:10.1086/376634 · Cited by 406
Walsh, T. J., Goodman, J. L., Pappas, P., Bekersky, I., Buell, D. N., Roden, M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401
Leishmania/HIV co-infections: epidemiology in Europe
Desjeux, P., & Alvar, J. (2003) · Annals of Tropical Medicine & Parasitology · doi:10.1179/000349803225002499 · Cited by 398
Dignani, M. C., & Anaissie, E. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00845.x · Cited by 352
Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351
Bowden, R., Chandrasekar, P., White, M. H., Li, X., Pietrelli, L., Gurwith, M., van Burik, J., Laverdiere, M., Safrin, S., & Wingard, J. R. (2002) · Clinical Infectious Diseases · doi:10.1086/341401 · Cited by 335
Amphotericin B-Induced Oxidative Damage and Killing of Candida albicans
Sokol-Anderson, M. L., Brajtburg, J., & Medoff, G. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/154.1.76 · Cited by 287
Caffrey, P., Lynch, S., Flood, E., Finnan, S., & Oliynyk, M. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00046-1 · Cited by 250
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial
Meunier, F., Prentice, H. G., & Ringden, O. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.83 · Cited by 247
Eriksson, U., Seifert, B., & Schaffner, A. (2001) · BMJ · doi:10.1136/bmj.322.7286.579 · Cited by 236
SCHWARZ, C. (1999) · Journal of Microencapsulation · doi:10.1080/026520499289185 · Cited by 235
AmBisome (Liposomal Amphotericin B): A Comparative Review
Boswell, G. W., Buell, D., & Bekersky, I. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04464.x · Cited by 227
Müller, R., Maaben, S., Weyhers, H., & Mehnert, W. (1996) · Journal of Drug Targeting · doi:10.3109/10611869609015973 · Cited by 222
Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.
Sawaya, B. P., Briggs, J. P., & Schnermann, J. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v62154 · Cited by 201
Bazile, D. V., Ropert, C., Huve, P., Verrecchia, T., Mariard, M., Frydman, A., Veillard, M., & Spenlehauer, G. (1992) · Biomaterials · doi:10.1016/0142-9612(92)90142-b · Cited by 200
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations
Barrett, J. P., Vardulaki, K. A., Conlon, C., Cooke, J., Daza-Ramirez, P., Evans, E. G. V., Hawkey, P. M., Herbrecht, R., Marks, D. I., Moraleda, J. M., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80125-x · Cited by 190
Formulation of amphotericin B as nanosuspension for oral administration
Kayser, O. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00686-5 · Cited by 186
Self-citationShort-Course Treatment of Visceral Leishmaniasis with Liposomal Amphotericin B (AmBisome)
Davidson, R. N., di Martino, L., Gradoni, L., Giacchino, R., Gaeta, G. B., Pempinello, R., Scotti, S., Cascio, A., Castagnola, E., Maisto, A., et al. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.6.938 · Cited by 163
Yardley, V., & Croft, S. L. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(99)00133-8 · Cited by 163
Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis
Santangelo, R., Paderu, P., Delmas, G., Chen, Z.-W., Mannino, R., Zarif, L., & Perlin, D. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2356-2360.2000 · Cited by 150
Schöler, N., Krause, K., Kayser, O., Müller, R. H., Borner, K., Hahn, H. H., & Liesenfeld, O. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1771-1779.2001 · Cited by 140
Self-citationFungal Sterols and the Mode of Action of the Polyene Antibiotics
Hamilton-Miller, J. M. T. (1974) · Advances in applied microbiology · doi:10.1016/s0065-2164(08)70556-2 · Cited by 138
Molecular Properties of Amphotericin B Membrane Channel: A Molecular Dynamics Simulation
Bagiński, M., Resat, H., & McCammon, J. A. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.4.560 · Cited by 131
Patterns of Amphotericin B Killing Kinetics against Seven Candida Species
Cantón, E., Pemán, J., Gobernado, M., Viudes, A., & Espinel‐Ingroff, A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2477-2482.2004 · Cited by 121
Brucellosis in a mother and her young infant: Probable transmission by breast milk
Palandüz, A., Palanduz, Ş., Güler, K., et al. (2000) · International Journal of Infectious Diseases · doi:10.1016/s1201-9712(00)90068-7 · Cited by 101
López‐Vélez, R., Videla, S., Márquez, M., Boix, V., Me, J.-M., Górgolas, M., Arribas, J. R., Salas, A., Laguna, F., Sust, M., et al. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh084 · Cited by 97
Adedoyin, A. B., Bernardo, J. F., Swenson, C. E., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2201 · Cited by 92
The lipid formulations of amphotericin B
Herbrecht, R., Natarajan‐Amé, S., Nivoix, Y., & Letscher‐Bru, V. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.8.1277 · Cited by 90
Hertenstein, B., Kern, W. V., Schmeiser, T., Štefanič, M., Bunjes, D. W., Wiesneth, M., Novotný, J., Heimpel, H., & Arnold, R. (1994) · Annals of Hematology · doi:10.1007/bf01695915 · Cited by 87
Formulation and characterization of amphotericin B–polyethylenimine–dextran sulfate nanoparticles
Tiyaboonchai, W., Woiszwillo, J., & Middaugh, C. R. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1042 · Cited by 85
Preparation, purification and morphology of polymeric nanoparticles as drug carriers
Venier‐Julienne, M., & Benoît, J. (1996) · Pharmaceutica Acta Helvetiae · doi:10.1016/0031-6865(95)00059-3 · Cited by 84
Milhaud, J., Ponsinet, V., Takashi, M., et al. (2002) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00416-3 · Cited by 81
Pharmakotherapie bei Haus- und Nutztieren
Löscher, W. 1., & Bäumer, W. 1. (2014) · Thieme eBooks · doi:10.1055/b-003-117816 · Cited by 80
Clemons, K. V., & Stevens, D. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.1047-1050.2004 · Cited by 77
ANTIFUNGAL SUSCEPTIBILITY TESTING
Pfaller, M. A., & Yu, W. L. (2001) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70192-6 · Cited by 77
Leishmaniasis in HIV infection.
Paredes, R., Muñoz, J., Diaz, I., Domingo, P., Gurguí, M., & Clotet, B. (2003) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.929 · Cited by 74
Erjavec, Z., Woolthuis, G., de Vries-Hospers, H. G., Sluiter, W. J., Daenen, S. M. G. J., de Pauw, B., & Halie, M. R. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01726364 · Cited by 72
Boswell, G. W., Bekersky, I., Buell, D. N., Hiles, R., & Walsh, T. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.263 · Cited by 72
Amphotericin B and its delivery by liposomal and lipid formulations
Gates, C., & Pinney, R. J. (1993) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.1993.tb00605.x · Cited by 70
Lipid Formulation as a Drug Carrier for Drug Delivery
Tomii, Y. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023395871 · Cited by 56
Ayestarán, A., López, R. M., Montoro, J. B., Estíbalez, A., Pou, L., Juliá, A., López, A., & Pascual, B. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.609 · Cited by 55
Segarra, I., Movshin, D. A., & Zarif, L. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10173 · Cited by 53
García, A. C., Adler‐Moore, J., & Proffitt, R. T. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2327-2332.2000 · Cited by 51
Warn, P. A., Sharp, A., Guinea, J., & Denning, D. W. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh153 · Cited by 49
Antifungal pharmacotherapy for invasive mould infections
Gallagher, J. C., Ashley, E. S. D., Drew, R. H., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.2.147 · Cited by 46
Disposition of Aerosolized Liposomal Amphotericin B
Lambros, M. P., Bourne, D. W. A., Abbas, S. A., & Johnson, D. L. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js9604218 · Cited by 44
Lack of Activity of Amphotericin B in Systemic Murine Fusarial Infection
Anaissie, E. J., Hachem, R., Legrand, C., Legenne, P., Nelson, P., & Bodey, G. P. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/165.6.1155 · Cited by 42
Zager, R. A. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.8967 · Cited by 40
In Vitro Antifungal Susceptibility Testing
Hoffman, H. L., & Pfaller, M. A. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.12.111s.34510 · Cited by 36
Bekersky, I., Fielding, R. M., Dressler, D. E., Kline, S., Buell, D. N., & Walsh, T. J. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/009127000104100906 · Cited by 35
Robbie, G., & Chiou, W. L. (1998) · Pharmaceutical Research · doi:10.1023/a:1011923704731 · Cited by 29
Weldon, J. S., Munnell, J. F., Hanson, W. L., & Alving, C. R. (1983) · Parasitology Research · doi:10.1007/bf00927697 · Cited by 29
Karyotakis, N. C., & Anaissie, E. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.11.2660 · Cited by 26
Carrillo-Muñoz, A.-J., Quindós, G., Tur‐Tur, C., Ruesga, M., Alonso, R., del Valle, O., Rodríguez, V., Arévalo, M. P., Salgado, J., Martín‐Mazuelos, E., et al. (2000) · Chemotherapy · doi:10.1159/000007295 · Cited by 25
Resistenzen und Resistenzmechanismen: Wie „entkommen”︁ Pilze der Therapie?
Morschhäuser, J. (2003) · Pharmazie in unserer Zeit · doi:10.1002/pauz.200390029 · Cited by 19
The effect of liposome-entrapped desferrioxamine onLeishmania donovani in vitro
Segovia, M., Navarro, A., & Artero, J. M. (1989) · Annals of Tropical Medicine and Parasitology · doi:10.1080/00034983.1989.11812357 · Cited by 19
Amphotericin B — Not So Terrible
Bishara, J., Weinberger, M., Lin, A. Y., & Pitlik, S. D. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.10240 · Cited by 18
Cited by
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
Ponte-Sucre, A., Gamarro, F., Dujardin, J.-C., Barrett, M. P., López-Vélez, R., García-Hernández, R., Pountain, A. W., Mwenechanya, R., & Papadopoulou, B. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006052 · Cited by 962
Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
Antifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2012) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 505
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani
Purkait, B., Kumar, A., Nandi, N., Sardar, A. H., Das, S., Kumar, S., Pandey, K., Ravidas, V., Kumar, M., De, T., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00030-11 · Cited by 324
Metadata
- Authors
- Lemke, A., Kiderlen, A. F., & Kayser, O.
- Venue
- Applied Microbiology and Biotechnology
- Published
- 2005-04-09
- Volume
- 68
- Issue
- 2
- Pages
- 151-162
- ISSN
- 0175-7598 (ISSN-L)
- 1432-0614
- OpenAlex
- W4210971654
- Cited by
- 305
- References
- 67
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.